{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:28:08Z","timestamp":1791041288509,"version":"4.1.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The co-occurrence of myeloid neoplasms and lymphoproliferative diseases (LPDs) has been epidemiologically described, particularly in myeloproliferative neoplasms (MPNs). However, the clinical features of these patients are poorly known. In this study, we evaluated a single-center cohort of 44 patients with a diagnosis of myeloid and LPD focusing on clinical features, therapy requirement, and outcome. The two diagnoses were concomitant in 32% of patients, while myeloid disease preceded LPD in 52% of cases (after a median of 37 months, 6\u2013318), and LPD preceded myeloid neoplasm in 16% (after a median of 41 months, 5\u2013242). The most prevalent LPD was non-Hodgkin lymphoma (50%), particularly lymphoplasmacytic lymphoma (54.5%), followed by chronic lymphocytic leukemia (27%), plasma cell dyscrasias (18.2%), and rarer associations such as Hodgkin lymphoma and Erdheim\u2013Chester disease. Overall, 80% of <jats:italic>BCR-ABL1<\/jats:italic>-negative MPN patients required a myeloid-specific treatment and LPD received therapy in 45.5% of cases. Seven subjects experienced vascular events, 13 a grade &amp;gt;\/= 3 infectious episode (9 pneumonias, 3 urinary tract infection, and 1 sepsis), and 9 developed a solid tumor. Finally, nine patients died due to solid tumor (four), leukemic progression (two), infectious complications (two), and brain bleeding (one). Longer survival was observed in younger patients (<jats:italic>p<\/jats:italic> = 0.001), with better performance status (<jats:italic>p<\/jats:italic> = 0.02) and in the presence of driver mutations (<jats:italic>p<\/jats:italic> = 0.003). Contrarily, a worse survival was significantly associated with the occurrence of infections (<jats:italic>p<\/jats:italic> &amp;lt; 0.0001). These data suggest that in subjects with co-occurrence of myeloid and lymphoid neoplasms, high medical surveillance for infectious complications is needed, along with patient education, since they may negatively impact outcome.<\/jats:p>","DOI":"10.3389\/fonc.2021.701604","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T13:53:50Z","timestamp":1634651630000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Co-Occurrence of Myeloid and Lymphoid Neoplasms: Clinical Characterization and Impact on Outcome. A Single-Center Cohort Study"],"prefix":"10.3389","volume":"11","author":[{"given":"Cristina","family":"Bucelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fattizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juri Alessandro","family":"Giannotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kordelia","family":"Barbullushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Pasquale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Barozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Barbanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Pettine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Gaia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Reda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Cassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma","family":"Barcellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-09-0353","article-title":"Increased Risk of Lymphoid Neoplasms in Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasms","volume":"18","author":"Vannucchi","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw072","article-title":"Incidence and Prognostic Impact of Other Cancers in a Population of Long-Term Survivors of Chronic Lymphocytic Leukemia","volume":"27","author":"Falchi","year":"2016","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008109","article-title":"The Pathobiology of Thrombosis, Microvascular Disease, and Hemorrhage in the Myeloproliferative Neoplasms","volume":"137","author":"Hasselbalch","year":"2021","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24978","article-title":"Driver Mutations and Prognosis in Primary Myelofibrosis: Mayo-Careggi MPN Alliance Study of 1,095 Patients","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am J Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia Vera and Essential Thrombocythemia: 2021 Update on Diagnosis, Risk-Stratification and Management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am J Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.033779","article-title":"Increased Risk of Lymphoid Neoplasm in Patients With Myeloproliferative Neoplasm: A Study of 1,915 Patients","volume":"96","author":"Rumi","year":"2011","journal-title":"Haematologica"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2016.07.006","article-title":"Myeloproliferative Neoplasms: Association With Lymphoproliferative Disorders; a Single Institution Experience","volume":"48","author":"Batt","year":"2016","journal-title":"Pathology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.09.015","article-title":"Coexistence of Myeloproliferative Neoplasm and Plasma-Cell Dyscrasia","volume":"14","author":"Malhotra","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.225839","article-title":"Myeloproliferative and Lymphoproliferative Malignancies Occurring in the Same Patient: A Nationwide Discovery Cohort","volume":"105","author":"Holst","year":"2020","journal-title":"Haematologica"},{"key":"B12","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/ajh.25049","article-title":"Lymphoproliferative Disorders in Patients With Chronic Myeloproliferative Neoplasms: A Systematic Review","volume":"93","author":"Marchetti","year":"2018","journal-title":"Am J Hematol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1486476","DOI":"10.1155\/2019\/1486476","article-title":"Coexistence of Myeloid and Lymphoid Neoplasms: A Single-Center Experience","volume":"2019","author":"Bouchla","year":"2019","journal-title":"Adv Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-845065","article-title":"Distinct Patterns of Clonal Evolution in Patients With Concurrent Myelo- and Lymphoproliferative Neoplasms","volume":"132","author":"Kennedy","year":"2018","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2009.11.003","article-title":"8p11 Myeloproliferative Syndrome: A Review","volume":"41","author":"Jackson","year":"2010","journal-title":"Hum Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01335-w","article-title":"Germline POT1 Variants can Predispose to Myeloid and Lymphoid Neoplasms","author":"Lim","year":"2021","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e3697","DOI":"10.1097\/MD.0000000000003697","article-title":"Erdheim-Chester Disease With Multiorgan Involvement, Following Polycythemia Vera: A Case Report","volume":"95","author":"Iurlo","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.05.004","article-title":"ABVD Associated With Imatinib for Coexisting Chronic Myeloid Leukaemia and Relapsed Hodgkin Lymphoma","volume":"34","author":"Ferrario","year":"2010","journal-title":"Leuk Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2701","article-title":"Myeloproliferative and Lymphoproliferative Disorders: State of the Art","volume":"38","author":"Rumi","year":"2020","journal-title":"Hematol Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1182\/blood-2017-10-810739","article-title":"Aggressive B-Cell Lymphomas in Patients With Myelofibrosis Receiving JAK1\/2 Inhibitor Therapy","volume":"132","author":"Porpaczy","year":"2018","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/s41375-019-0487-8","article-title":"Second Cancer in Philadelphia Negative Myeloproliferative Neoplasms (MPN-K). A Nested Case-Control Study","volume":"33","author":"Barbui","year":"2019","journal-title":"Leukemia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.701604\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T13:53:52Z","timestamp":1634651632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.701604\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":21,"alternative-id":["10.3389\/fonc.2021.701604"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.701604","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]},"article-number":"701604"}}